Quest Diagnostics Incorporated

DGX Healthcare Diagnostics & Research

Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.

Revenue
+9.98%
EPS
+29.4%
Free cash flow
+6.21%
Total debt
−2.20%

Quarter to September 2026, against a year earlier

254.71 0.03 −0.01%
Market cap
$28.0B
P/E
25.0×
Fwd P/E
24.4×
Dividend yield
1.33%
F-score
8/9
Altman Z
3.15
Beneish M
−2.65
Dividend safety
85/100

Quest Diagnostics Incorporated 8-K filed Oct 22, 2026

Period ended Oct 21, 2026 · Filed · accepted 6:53 AM ET · Document on sec.gov · Filing index

8.01 Other events

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov